Tesamorelin Research
Tesamorelin is a stabilized synthetic analog of growth-hormone-releasing hormone (GHRH) studied in laboratory and in-vitro models as a probe of the hypothalamic-pituitary-GH axis. For research use only.
Also known as: TH9507 · CAS 218949-48-5
Tesamorelin is a GHRH(1-44) analog carrying an N-terminal trans-3-hexenoyl modification that resists DPP-4 cleavage. In experimental and cell models it binds the GHRH receptor on pituitary somatotrophs, activating Gs/cAMP/PKA signaling and increasing GH release, with downstream IGF-1 as a measured readout.
Mechanism of Action
In experimental systems, tesamorelin engages the GHRH receptor (GHRHR), a Gs-coupled GPCR on anterior-pituitary somatotrophs. Receptor activation raises intracellular cAMP and triggers PKA-dependent signaling that promotes synthesis and pulsatile release of endogenous growth hormone. The N-terminal trans-3-hexenoyl group differentiates tesamorelin from native GHRH by conferring resistance to dipeptidyl-peptidase-4 (DPP-4) degradation, giving the analog greater stability in vitro and in experimental models. Because it acts upstream on the GH axis rather than supplying exogenous GH, researchers use tesamorelin to study intact negative-feedback loops, somatostatin counter-regulation, and the kinetics of GH/IGF-1 output under controlled laboratory conditions.
Research Applications
Tesamorelin is used in laboratory and in-vitro work as a reference GHRH-axis agonist. Reported research areas include visceral and hepatic lipid metabolism, where experimental-model studies examine reductions in adipose and liver fat fractions, and transcriptomic/proteomic profiling of inflammation, tissue-repair, and oxidative-phosphorylation gene sets in fatty-liver models. Investigators also use it to characterize GH pulsatility, IGF-1 dynamics, and the relationship between GH signaling and protein turnover, mitochondrial activity, and lipolysis in cultured cells and experimental systems. These uses are strictly laboratory-based and make no representation of human therapeutic effect.
Handling & Stability
Tesamorelin is typically supplied as a lyophilized powder for laboratory preparation with bacteriostatic or sterile water, after which working aliquots are commonly kept frozen to limit freeze-thaw cycles. As a peptide, it is sensitive to heat, repeated thawing, and prolonged light exposure; researchers generally store lyophilized material cold and prepared solution refrigerated for short windows. Its DPP-4-resistant N-terminal modification is the structural basis for improved bench stability relative to native GHRH. This product is intended for in-vitro and experimental research only and is not formulated, labeled, or approved for human administration.
Applications at a glance
- Laboratory study of GHRH-receptor activation and GH/IGF-1 output
- In-vitro hepatic and adipose lipid-metabolism research
- Transcriptomic / proteomic profiling in fatty-liver experimental models
- Investigation of GH-axis feedback and pulsatility